Inside every cell, proteins are constantly condensing into liquid droplets and then dissolving back, a cycle essential for life itself. When this switching mechanism breaks down, diseases like ALS and Alzheimer's can take hold. A research team at Tokushima University has developed a world-first tool called OptoChaperone that uses light alone to reversibly switch these droplets on and off. As U.S. and European startups pour hundreds of millions of dollars into "condensate drug discovery," Japan has just contributed a uniquely powerful piece of the puzzle.

What are "protein droplets," exactly?

Inside cells, proteins and RNA molecules can spontaneously cluster together to form tiny liquid-like droplets, a phenomenon called liquid-liquid phase separation (LLPS).

Think of a vinaigrette: oil and vinegar separate into distinct phases without any membrane between them. Something very similar happens inside living cells, where proteins coalesce into compartments with concentrations very different from their surroundings. Despite having no membrane, these "membraneless organelles" play major roles in stress response, gene expression, and signal transduction. The discovery has rewritten cell biology textbooks over the past decade.

The trouble begins when these droplets fail to dissolve properly. What should be a reversible, fluid state solidifies into irreversible protein aggregates. When these aggregates build up in nerve cells, they can trigger neurodegenerative diseases including ALS (amyotrophic lateral sclerosis), Alzheimer's disease, and Parkinson's disease.

Why previous tools couldn't solve the mystery

Scientists have been using optogenetics, tools that use light to control proteins, to study droplets for several years. Multiple tools exist that can trigger droplet formation on demand using light.

But "forming" droplets alone wasn't enough. To understand how diseases actually develop, researchers needed to answer a harder question: once a droplet forms, can it be dissolved? Under what conditions does it turn into toxic aggregates?

Answering that required the ability to dissolve droplets on command, something that proved frustratingly difficult for years.

How OptoChaperone opens a new door

The research team at Tokushima University's Institute of Advanced Medical Sciences, Prof. Tomohide Saio, Assistant Prof. Motonori Matsusaki, and graduate student Do Thanh Tuan, tackled the problem with a creative twist.

Their key insight involved molecular chaperones, proteins that act as "helpers" inside cells. Chaperones normally guide other proteins into their correct folded shapes and prevent harmful aggregation. Recent research has shown they can also help dissolve droplets.

The team started with a bacterial chaperone called Trigger Factor (TF), attached an azobenzene derivative, a chemical whose 3D shape changes depending on light wavelength, and fused a "lid protein" onto it. The result: OptoChaperone.

Here's how it works:

  • Shine visible light (450nm, blue) → the lid opens → chaperone is activated (ON) → droplets are dissolved
  • Shine UV light (365nm) → the lid closes → chaperone is deactivated (OFF) → droplets are allowed to form

Simply by switching the light color, researchers can toggle droplets on and off repeatedly. This reversible, bidirectional control is the world's first of its kind.

Tested on ALS-linked proteins

The team validated OptoChaperone on three proteins closely tied to ALS and stress response:

  • FUS (Fused in Sarcoma), a known causative gene in familial ALS
  • TDP-43, abnormally aggregates in over 97% of ALS patients, often called "the signature protein of ALS"
  • HSF1, a stress-responsive transcription factor

Both in test tubes (in vitro) and inside living cells (in cells), the team showed that droplets could be formed and dissolved at will just by switching the light. No chemical additives. No genetic modifications to the target proteins. Pure light control.

Cell experiments also revealed something striking: OptoChaperone's droplet control directly affects whether cells survive or die under heat stress. This is the first demonstration that LLPS regulation is literally a life-or-death matter for cells.

The findings were published online on April 20, 2026, in the prestigious American Chemical Society journal Journal of the American Chemical Society (JACS).

The global "condensate drug discovery" race

Targeting LLPS for drug discovery has become one of the hottest areas in biotech. Since around 2018, a wave of specialized startups has launched in the U.S. and Europe.

Dewpoint Therapeutics: the field's leading company

Boston-based Dewpoint Therapeutics, founded in 2019, was co-founded by Tony Hyman of Germany's Max Planck Institute (a pioneer of LLPS biology) and Rick Young of MIT's Whitehead Institute. The company develops what it calls "c-mods" (condensate-modifying drugs), small molecules targeting dysfunctional droplets.

Dewpoint has raised approximately $287 million across three funding rounds and inked major partnerships: a $100 million deal with Germany's Bayer, plus collaborations with Merck & Co., Pfizer, and Denmark's Novo Nordisk.

There's a Japanese angle here too: in December 2024, Mitsubishi Tanabe Pharma entered a research collaboration with Dewpoint focused on ALS, targeting the TDP-43 protein. In January 2026, Dewpoint announced its TDP-43 condensate modulator had reached Development Candidate status, marking a major milestone for ALS, frontotemporal dementia (FTD), and traumatic brain injury treatment.

Nereid Therapeutics: the physics-driven approach

Nereid Therapeutics launched in November 2020 with $50 million from Apple Tree Partners. It was co-founded by Clifford Brangwynne of Princeton, the scientist who, back in 2009, first showed that LLPS drives membraneless organelle formation.

Nereid's unique angle: "a marriage of soft matter physics with cell biology." The company uses optogenetics to visualize and quantify condensate formation inside mammalian cells, conceptually similar to OptoChaperone, but focused squarely on drug screening.

Others: Faze, Transition Bio, and more

Other entrants include Faze Medicines (launched December 2020 with $81 million, targeting ALS and myotonic dystrophy type 1) and Cambridge, UK-based Transition Bio. Notably, Faze shut down in 2022, a reminder that this field still faces significant scientific and commercial hurdles.

Japan's strategic angle: not drugs, but the toolbox

Here's what makes OptoChaperone strategically interesting.

Dewpoint, Nereid, and others aim to create drugs that directly target dysfunctional droplets. OptoChaperone, by contrast, is a tool for understanding how droplets work in the first place. That might sound less glamorous, but it's arguably more fundamental.

The biggest challenge facing condensate drug discovery today is proving that droplet dysfunction causes disease, not just correlates with it. With OptoChaperone, researchers can freely toggle droplet formation and dissolution while observing cellular and animal responses. That makes it a potential standard tool for every condensate-focused biotech on the planet to validate their drug hypotheses.

It's the "selling pickaxes during a gold rush" strategy. The people who got rich during the California Gold Rush weren't the miners, they were the ones selling picks, shovels, and jeans. Japan may be quietly positioning itself to support the foundational research of pharma companies worldwide.

ALS in Japan and globally

ALS is a designated "intractable disease" (shitei-nanbyō) in Japan, with roughly 10,000 patients estimated nationwide. About 1,000–2,000 new cases are diagnosed each year. Median survival from onset is 2–5 years, with most patients eventually requiring mechanical ventilation due to respiratory failure. Available drugs (riluzole, edaravone) can only slow progression, there is no cure.

Globally, ALS cases were estimated at over 222,000 in 2015, and are projected to exceed 376,000 by 2040 as populations age. In the U.S. alone, approximately 30,000 people currently live with ALS.

Japan's JaCALS (Japanese Consortium for Amyotrophic Lateral Sclerosis research) registry had enrolled 2,625 patients as of August 2025, combining clinical data with genetic information in one of the world's largest natural-history studies of the disease. New tools like OptoChaperone strengthen the foundation on which future Japanese drug discovery can be built.

What comes next

The Tokushima team sees OptoChaperone contributing to:

  • Understanding neurodegeneration: ALS, Alzheimer's, Parkinson's, Huntington's, and other diseases involving abnormal protein aggregation
  • Drug discovery: screening for compounds that promote droplet dissolution
  • Basic biology: stress response, signal transduction, cellular decision-making
  • Oncology applications: some cancers also involve condensate dysfunction

The research was funded by the Japan Society for the Promotion of Science (JSPS), the Japan Agency for Medical Research and Development (AMED), the Japan Science and Technology Agency (JST), and private foundations, including the Serika Fund, a citizen-led ALS research fund inspired by a character from the popular manga Space Brothers (Uchū Kyōdai).

A note for international readers

Neurodegenerative diseases are a shared global challenge. Ever since the 2014 ALS Ice Bucket Challenge brought worldwide attention to the disease, cross-border research collaboration has accelerated.

OptoChaperone might sound like something out of science fiction, controlling protein behavior with light alone, but it's a very real product of Japanese basic research. While American and European pharma giants pour billions into the condensate drug race, Japan is contributing something uniquely valuable: the tools everyone else will need.

How is neurodegenerative disease research funded in your country? Are there public programs or major drug development initiatives around ALS or dementia where you live? Let us know in the comments.

References